Preclinical studies demonstrate that co-inhibition of A2AR and PD-1 significantly boosts T cell metabolic fitness, reverses T cell exhaustion, and increases the tumor-killing capacity of adoptively transferred T cells in murine cancer models [2]. Here, ADORA2A is linked to cancer.